Klein Lawrence Otto

Insider trading profile for Klein Lawrence Otto: PRINCIPAL (historical) = CRISPR Therapeutics (CRSP, 85 tx, 2019-2022): 280,037 shares sold, 12,500 acquired = 22:1 sell ratio — systematic SPAC/IPO lockup distribution at $61-$118 range across 2021-2022 peaks, with zero conviction hold through CRISPR's $30→$200 run. Dyne Therapeutics (DYN, 8 tx, 2020-2022): 35,574 A-code acquisitions at $0 FMV. Jasper Therapeutics (JSPR, 3 tx, 2022-2023): 78,045 (Mar 2022) + 24,500 (Oct 2022) + 47,000 (Jun 2023) = 149,545 A-code at $0 FMV. Oruka Therapeutics (ORKA, 2 tx 2025 + 1 tx 2026): Jan 2025 A-code 230,000 at $12.50 FMV concentrated bet; Jun 2026 S-code 1,729 at $69.69 (first monetization, retaining bulk). Jade Biosciences (JBIO, 1 tx Apr 2025): A-code 23,017 at $0 FMV. KEY SIGNAL: Post-CRSP exit, the insider redeployed systematically into a gene-therapy cluster (DYN → JSPR → ORKA → JBIO). Total A-code accumulation: 412K shares across 4 vehicles at $0-$12.50 FMV. ORKA represents the largest single bet (230K at $12.50 = $2.88M FMV) and is now at $69.69 (5.6x) with partial monetization (1.7K of 230K = <1% of position taken off). The ORKA partial sell, while small in absolute terms, signals some profit-taking at a 5x return. Classification: mixed -- the cluster-across-gene-therapy pattern is bullish industry conviction, but the ORKA profit-taking at 5x FMV introduces a top-taking element that softens the bullish read. Net is mixed rather than purely bullish.